
    
      This is a randomized, double-blind, placebo-controlled, parallel-group study of adolescents
      with ADHD who have genetic disorders impacting mGluRs. Approximately 90 subjects will receive
      randomized treatment with NFC-1 or placebo. Dosing will be optimized during the first 4 weeks
      of treatment, based on clinical response and tolerability, and maintained for an additional 2
      weeks.
    
  